Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: NNC0385-0434 A 15 mgOther: Placebo I A (for NNC0385-0434 A 40 mg)Other: Placebo I A (for NNC0385-0434 A 15 mg)Drug: NNC0385-0434 A 40 mgDrug: NNC0385-0434 A 100 mgOther: Placebo II A (for NNC0385-0434 A 100 mg)
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 255
- Registration Number
- NCT04992065
- Locations
- 🇺🇸
Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
🇩🇪MVZ CCB Frankfurt Und Main-Taunus GbR, Frankfurt, Germany
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Cagrilintide 2.4 mgDrug: Placebo (semaglutide)Drug: Placebo (cagrilintide)
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 92
- Registration Number
- NCT04982575
- Locations
- 🇺🇸
Macoupin Research Group, Gillespie, Illinois, United States
🇺🇸Accellacare, Wilmington, North Carolina, United States
🇺🇸Clinical Trial Research Associates,Inc, Plantation, Florida, United States
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
- Conditions
- OverweightObesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3400
- Registration Number
- NCT04972721
- Locations
- 🇮🇹
Master Centre for Italy, Rome, Italy
🇯🇵Master Centre for Japan, Tokyo, Japan
🇱🇻MAster Centre for Latvia, Marupes, Latvia
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
- Conditions
- Growth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 110
- Registration Number
- NCT04970654
- Locations
- 🇨🇳
Hunan Children's Hospital, Changsha, Hunan, China
🇨🇳Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 120
- Registration Number
- NCT04969939
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸Jacksonville Ctr For Clin Res, Jacksonville, Florida, United States
🇺🇸Endo Res Solutions Inc, Roswell, Georgia, United States
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 750
- Registration Number
- NCT04952779
- Locations
- 🇰🇷
KangNam Sacred Heart Hospital, Seoul, Korea, Republic of
🇰🇷Isam Hospital, Busan, Korea, Republic of
🇰🇷Dongtan Jeil Women's Hospital, Hwasung-si, Korea, Republic of
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- Conditions
- Obesity & Overweight
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT04940078
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
🇨🇦Altasciences Company Inc., Montreal, Quebec, Canada
Compassionate Use of Concizumab if You Have Haemophilia
- Conditions
- Congenital Haemophilia
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT04921956
- Locations
- 🇺🇸
University of California San Francisco UCSF, San Francisco, California, United States
🇺🇸Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸Memorial Health University Medical Center, Savannah, Georgia, United States
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (Semaglutide)
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 617
- Registration Number
- NCT04916470
- Locations
- 🇮🇳
Gandhi Memorial Hospital- King George's Medical University, Lucknow, Uttar Pradesh, India
🇮🇳G B Pant Institute of Postgraduate Medical Education and Res, New Delhi, India
🇮🇳Max Super Speciality Hospital_New Delhi, New Delhi, India
Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT04892069
- Locations
- 🇱🇧
Novo Nordisk Investigational Site, Beirut, Hamra, Beirut, Lebanon